• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
Development of Biosimilars for Global Market

Biosimilars are biologic medicines that are highly similar to existing licensed biologic products with no clinically meaningful differences in the terms of safety and efficacy.

However, the process of introducing a biosimilar to an innovator product is far more complex than the relatively straightforward process of introducing a generic equivalent to an innovator product based on a new chemical entity. Biosimilars are being developed by an abbreviated route of development, that can help to have cost effective & more access to the potential patients. With $67 billion in global sales of biologic medicines anticipated to go off patent by 2020, even modest reductions in the cost of biosimilars products could have a meaningful impact on health care systems around the world. For physicians and their patients, biosimilars provide additional therapeutic options.

For more details, download White Paper here:

pdf-8Data integrity for supply chain operations, Powered by blockchain technology
Only registered and logged in users can download this file.